The company has signed a distribution agreement with BL&H for sales and marketing of Spherotide in South Korea.

Xbrane will receive mid-single digit SEK million license fee for the exclusive rights to Spherotide in South Korea and Xbrane and BL&H will share the profits from sales.

“We are convinced that BL&H, with its strong position and experience in sales of hospital products, is the right partner for sales and marketing of Spherotide in South Korea,” said Martin Åmark, CEO Xbrane.

Spherotide is a generic version of long acting triptorelin and is used primarily in the treatment of prostate cancer, endometriosis, breast cancer and uterine fibroids. Triptorelin in its different strengths had sales of USD 12 Million in South Korea during 2016.

Timing of launch is expected to earliest 2019.